🔴 Context Therapeutics is trading 5.8% down in pre-market with no confirmed company-specific catalyst

Context Therapeutics is trading at $0.41, down -5.83% in pre-market on August 26, 2026, with no confirmed company-specific catalyst identified.

• The latest major company release, on August 5, reported a $14.6 million net loss and discontinuation of CT-95 development.
• Broader futures are only modestly mixed, leaving the decline’s immediate cause unclear.